Company intelligence / Profile preview

Mirecule Therapeutics

Gaithersburg, Maryland, United States

Ownership: Private
Employees: ~15
Development stage: Other

Overview

Mirecule is a preclinical-stage biotechnology company focused on developing a new class of RNA therapeutics through its proprietary M-Scribe platform. The company specializes in creating antibody-RNA conjugates (ARCs) that enable the targeted delivery of RNA payloads to specific tissues, overcoming traditional delivery challenges in the field. Their lead program, MC-15, targets GDF15 for the treatment of cancer cachexia, a debilitating muscle-wasting syndrome. By leveraging genomic data and advanced conjugation chemistry, Mirecule aims to address high-unmet-need indications in oncology and beyond.

Therapeutic areas: Oncology
Modalities: RNA therapyAntibody-RNA conjugateSmall interfering RNA
Industry: Biotech

Beyond the preview

Go deeper on Mirecule Therapeutics.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mirecule Therapeutics.

Explore the full profile